Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood–labyrinth barrier disruption in a mouse model of chronic kidney disease

Ye Ding, Xin Jiang, Xiangming Ye

Open source

DOI
10.1007/s10735-026-10963-4
Published
2026-08-30
Container
Journal of Molecular Histology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10735-026-10963-4,
  title = {Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood–labyrinth barrier disruption in a mouse model of chronic kidney disease},
  author = {Ye Ding and Xin Jiang and Xiangming Ye},
  year = {2026},
  journal = {Journal of Molecular Histology},
  doi = {10.1007/s10735-026-10963-4},
  url = {https://doi.org/10.1007/s10735-026-10963-4}
}

RIS

TY  - JOUR
TI  - Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood–labyrinth barrier disruption in a mouse model of chronic kidney disease
AU  - Ye Ding
AU  - Xin Jiang
AU  - Xiangming Ye
PY  - 2026
JO  - Journal of Molecular Histology
DO  - 10.1007/s10735-026-10963-4
UR  - https://doi.org/10.1007/s10735-026-10963-4
ER  - 

APA

Ding, Y., Jiang, X., & Ye, X. (2026). Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood–labyrinth barrier disruption in a mouse model of chronic kidney disease. Journal of Molecular Histology. https://doi.org/10.1007/s10735-026-10963-4

Source records